New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNonapeptide-1 vs Dermorphin

Nonapeptide-1 vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Nonapeptide-1
Recovery & Repair
Dermorphin
Summary
Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
Not applicable (topical)
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
Topical
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
0.05–0.5% concentration in formulation
Not established for human use; research doses vary widely
Frequency
Twice daily
Not established
Key Benefits
  • Inhibits UV-induced tanning and hyperpigmentation
  • Reduces hormonal melasma
  • Evens skin tone at receptor level
  • Well-tolerated with minimal irritation
  • Complementary to tyrosinase inhibitors for enhanced brightening
  • Reduces post-inflammatory hyperpigmentation
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Generally very well-tolerated
  • Rare contact sensitivity in susceptible individuals
  • Theoretical risk of excessive depigmentation with prolonged high-concentration use
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With